<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04446858</url>
  </required_header>
  <id_info>
    <org_study_id>NECTAR</org_study_id>
    <nct_id>NCT04446858</nct_id>
  </id_info>
  <brief_title>Non-invasive Evaluation of the Predictive Value of CEUS and SWE in ACLF, Renal Failure and Hepatorenal Syndrome</brief_title>
  <acronym>NECTAR</acronym>
  <official_title>Non-invasive Evaluation of the Predictive Value of CEUS and SWE in Patients With and Without TIPS With ACLF, Renal Failure and Hepatorenal Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of non-invasive prognostic parameters in patients developing ACLF and renal
      failure in patients receiving and not receiving transjugular intrahepatic portosystemic shunt
      (TIPS). Patients are cared according to the local standardized follow up program. Clinical
      and laboratory data from standard patient care are evaluated for potential prognostic value.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NECTAR consists of patients with ACLF and renal failure with and without receiving
      transjugular intrahepatic portosystemic shunt (TIPS) at the Department of Internal Medicine
      I, University of Bonn, Germany and receiving a structured routine evaluation and follow up
      program. The diagnosis of cirrhosis was based on clinical, hemodynamic and biochemical
      parameters, and ultrasound and/or biopsy criteria.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>up to 10 years</time_frame>
    <description>death, liver transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ascites</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Evaluation of amount of ascites according to the Child-Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic Encephalopathy</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Evaluation of the grade according to the West Haven Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variceal Bleeding</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Assessment of presence of variceal bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Failure</measure>
    <time_frame>up to 10 years</time_frame>
    <description>defined as Bilirubin level ≥ 12mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute-on-Chronic Liver Failure</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Presence of ACLF according to the EASL-Chronic liver Failure Consortium (CLIF)-criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Failure</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Assessment of AKI according to KDIGO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ Failures</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Assessment of Organ failures according to CLIF-Sequential Organ Failure Assessment (SOFA) Score</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Kidney Failure, Acute</condition>
  <arm_group>
    <arm_group_label>With TIPS</arm_group_label>
    <description>Prospective cohort that received TIPS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without TIPS</arm_group_label>
    <description>Prospective cohort that did not receive TIPS</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, plasma, urine, ascites, stool, DNA, PBMC, Buffi coat
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with portal hypertension and kidney failure are eligible for inclusion
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with portal hypertension and kidney failure

        Exclusion Criteria:

          -  no consent, no kidney failure, no portal hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Praktiknjo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bonn</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Praktiknjo, MD</last_name>
    <phone>+49(0)228-287 15770</phone>
    <email>michael.praktiknjo@ukbonn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johannes Chang, MD</last_name>
    <phone>+49(0)228-287 15770</phone>
    <email>johannes.chang@ukbonn.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Praktiknjo, MD</last_name>
      <phone>+49228 28715770</phone>
      <email>michael.praktiknjo@ukbonn.de</email>
    </contact>
    <contact_backup>
      <last_name>Johannes Chang, MD</last_name>
      <phone>+49228 28715770</phone>
      <email>johannes.chang@ukbonn.de</email>
    </contact_backup>
    <investigator>
      <last_name>Nina Böhling, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 22, 2020</study_first_submitted>
  <study_first_submitted_qc>June 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Michael Praktiknjo</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>transjugular intrahepatic portosystemic shunt (TIPS)</keyword>
  <keyword>non-invasive assessments</keyword>
  <keyword>circulating biomarkers</keyword>
  <keyword>Transthoracic echocardiography (TTE) with Speckle-tracking</keyword>
  <keyword>Elastography</keyword>
  <keyword>Contrast-enhanced ultrasound</keyword>
  <keyword>Computer tomography scan (CT-scan)</keyword>
  <keyword>Magnetic resonance imaging (MRI)</keyword>
  <keyword>Urine biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatorenal Syndrome</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

